On June 10, 2021, Bartolome-Nebreda, Jose Manuel; Trabanco-Suarez, Andres Avelino; De Lucas Olivares, Ana Isabel published a patent.Related Products of 1227595-34-7 The title of the patent was Synthesis of heterocyclic Oga inhibitors treating tauopathies, in particular Alzheimer’s and Parkinson’s diseases. And the patent contained the following:
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors I, tautomers, or stereoisomers such that Ra can be a six- or five-membered heteroaryl ring system or nine, ten membered bicyclic heterocyclic ring; L is selected from O, OCH2, or CH2O; R1a-b an R2a-b are independently H, Me or (un)substituted C1-3 alkyl; R is H or methyl; Rb can be a bicyclic heteroaryl ring systems are prepared as pharmaceutically acceptable salts and solvates. Of note, II was prepared for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer’s disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathol., in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson’s disease, dementia due to Parkinson’s (or neurocognitive disorder due to Parkinson’s disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher’s disease. The experimental process involved the reaction of 4-(Chloromethyl)-2-methoxy-6-methylpyridine(cas: 1227595-34-7).Related Products of 1227595-34-7
The Article related to heterocyclic oga inhibitor preparation alzheimers parkinson tauopathy, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Two Hetero Atoms and other aspects.Related Products of 1227595-34-7